stoxline Quote Chart Rank Option Currency Glossary
  
Clearmind Medicine Inc. (CMND)
2.44  0.28 (12.96%)    01-13 16:00
Open: 2.15
High: 2.44
Volume: 67,973
  
Pre. Close: 2.16
Low: 2.15
Market Cap: 0(M)
Technical analysis
2026-01-14 7:44:17 AM
Short term     
Mid term     
Targets 6-month :  4.41 1-year :  5.88
Resists First :  3.78 Second :  5.03
Pivot price 2.28
Supports First :  1.74 Second :  1.45
MAs MA(5) :  2.38 MA(20) :  2.38
MA(100) :  24.51 MA(250) :  35.72
MACD MACD :  -1.8 Signal :  -2.5
%K %D K(14,3) :  53.3 D(3) :  55
RSI RSI(14): 28.4
52-week High :  63.2 Low :  1.74
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CMND ] has closed below upper band by 35.2%. Bollinger Bands are 89.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 23 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.65 - 2.66 2.66 - 2.68
Low: 2.11 - 2.13 2.13 - 2.15
Close: 2.41 - 2.44 2.44 - 2.47
Company Description

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Headline News

Wed, 31 Dec 2025
Clearmind Medicine Inc. Regains Compliance with Nasdaq Listing Requirements - Quiver Quantitative

Wed, 31 Dec 2025
Clearmind Medicine Regains Compliance with Nasdaq Minimum Bid Price Requirement - Yahoo Finance

Wed, 24 Dec 2025
Clearmind Medicine Inc. Reflects on Major Progress in 2025 Clinical Trials for CMND-100 Targeting Alcohol Use Disorder | CMND Stock News - Quiver Quantitative

Tue, 16 Dec 2025
Clearmind Medicine (Nasdaq: CMND) fills 2nd CMND-100 AUD trial cohort - Stock Titan

Tue, 16 Dec 2025
Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100 - Yahoo Finance

Thu, 11 Dec 2025
Why Did Clearmind Medicine Shares Plunge 29% After Hours? - Benzinga

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 2 (M)
Shares Float 0 (M)
Held by Insiders 25.6 (%)
Held by Institutions 0.4 (%)
Shares Short 28 (K)
Shares Short P.Month 71 (K)
Stock Financials
EPS -30
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.92
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -59.7 %
Return on Equity (ttm) -178.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -3.86
Qtrly Earnings Growth 0 %
Operating Cash Flow -5 (M)
Levered Free Cash Flow -4 (M)
Stock Valuations
PE Ratio -0.09
PEG Ratio 0
Price to Book value 0.3
Price to Sales 0
Price to Cash Flow -0.81
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android